ORY Oryzon Genomics S.A.
2.708EUR-1.02%Mkt Cap: 241.24M $P/E: —Today
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hemato…
Industry Peers
Biotechnology$127.85BUSDP/E 29.4
$75.86BUSD
$75.69BUSDP/E 18.2
$57.51BUSDP/E 35.1
$55.45BUSDP/E 35.2
$44.29BUSD
$42.34BUSDP/E 18.1
$40.51BUSDP/E 63.9
$33.03BUSDP/E 30.7
$29.40BUSDP/E 38.3
$25.80BUSD
$24.34BUSD
$24.27BUSD
$23.37BUSDP/E 14.7
$21.69BUSDP/E 27.4
$20.52BUSDP/E 27.1
$15.30BUSDP/E 16.1
$14.99BUSDP/E 17.8
$14.47BUSDP/E 18.4
$13.37BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
EEstrategias de Inversión | ||
EEstrategias de Inversión | ||
EEstrategias de Inversión | ||
EEstrategias de Inversión | ||
EEstrategias de Inversión | ||
EEstrategias de Inversión | ||